Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Smith & Nephew Snats ( (SNN) ) has shared an update.
On May 6, 2025, Elga Loher, Chief HR Officer of Smith & Nephew plc, sold 25,222 ordinary shares at a price of £10.700811 each on the London Stock Exchange. This transaction, disclosed in compliance with the UK Market Abuse Regulation, highlights the company’s adherence to regulatory requirements and may influence stakeholder perceptions regarding insider activities.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats receives a solid overall score of 77.0, driven by strong financial performance and positive earnings call sentiment. The company’s impressive revenue and profit growth, coupled with innovation-driven strategies, contribute to a favorable outlook. However, high valuation ratios and technical analysis indicators suggest caution. Challenges in the China market and input cost pressures in Orthopedics remain key risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company based in Watford, England. It specializes in the production of advanced wound management products, surgical devices, and orthopedic reconstruction solutions, serving healthcare professionals and patients worldwide.
Average Trading Volume: 917,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.47B
For an in-depth examination of SNN stock, go to TipRanks’ Stock Analysis page.